pyrroles has been researched along with Kidney Failure in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 5 (26.32) | 2.80 |
| Authors | Studies |
|---|---|
| Pei, Q; Xie, JL; Yang, GP; Zhang, H | 1 |
| Srinivas, NR | 1 |
| Barbour, AM; Chen, X; Epstein, N; Marbury, T; Petusky, S; Punwani, N; Srinivas, N; Xun, Z; Yeleswaram, S; Yuska, B; Zhou, G | 1 |
| Huang, J; Li, Y; Pei, Q; Tan, H; Wang, J; Wang, Y; Yang, G; Yu, J; Zhang, H | 1 |
| Chen, X; Epstein, N; Ji, T; Overholt, H; Punwani, N; Rockich, K; Wang, P; Yeleswaram, S | 1 |
| Huang, J; Li, W; Liu, WY; Pei, Q; Tan, HY; Wang, Y; Xie, JL; Yang, GP; Yang, XY; Zhang, H | 1 |
| Beckebaum, S; Cicinnati, VR; Kabar, I; Radtke, A | 1 |
| Ahn, CW; Cha, BS; Cho, Y; Choe, EY; Huh, KH; Kang, ES; Kim, MS; Kim, YS; Kwon, O; Lee, HC; Wang, HJ | 1 |
| Bae, WK; Kim, HR; Kim, HY; Kim, KH; Lee, HJ; Lee, S; Lim, HY; Rha, SY; Sun, JM | 1 |
| Choi, BS | 1 |
| Baek, SH; Han, JS; Joo, KW; Kim, DK; Kim, H; Kim, TM; Kim, YS; Lee, J; Lee, SH; Oh, KH | 1 |
| Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R | 1 |
| Bortlicek, Z; Buchler, T; Coufal, O; Dusek, L; Fiala, O; Kiss, I; Kubackova, K; Lakomy, R; Melichar, B; Pavlik, T; Poprach, A; Svoboda, M; Vyzula, R; Zemanova, M | 1 |
| Deedwania, P; Singh, V | 1 |
| Etienne-Grimaldi, MC; Izzedine, H; Milano, G; Renée, N; Vignot, S | 1 |
| Bukowski, R; Elson, P; Garcia, J; Golshayan, A; Khan, G; Rini, B; Wood, L | 1 |
| Arisz, L; Kastelein, JJ; Koopman, MG; Ozsoy, RC | 1 |
| Bernd, C; Miles, S; Noy, A; Politsmakher, A; von Roenn, J | 1 |
| Abel, RB; Horton, M; Moore, S; Olson, SC; Stern, RH; Yang, BB | 1 |
2 review(s) available for pyrroles and Kidney Failure
| Article | Year |
|---|---|
Calcineurin inhibitors in liver transplantation - still champions or threatened by serious competitors?
Topics: Abatacept; Calcineurin Inhibitors; Everolimus; Humans; Immunoconjugates; Immunosuppression Therapy; Liver Transplantation; Mycophenolic Acid; Precision Medicine; Pyrroles; Quinazolines; Renal Insufficiency; Risk Factors; Sirolimus; Tacrolimus; TOR Serine-Threonine Kinases | 2013 |
Expanding roles for atorvastatin.
Topics: Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Renal Insufficiency; Stroke | 2008 |
2 trial(s) available for pyrroles and Kidney Failure
| Article | Year |
|---|---|
Evaluation of the pharmacokinetics of pemigatinib in patients with impaired hepatic or renal function.
Topics: Area Under Curve; Chromatography, Liquid; Humans; Kidney; Kidney Failure, Chronic; Liver Diseases; Morpholines; Pyrimidines; Pyrroles; Renal Insufficiency; Tandem Mass Spectrometry | 2022 |
Pharmacokinetic study of imrecoxib in patients with renal insufficiency.
Topics: Adult; Aged; Cyclooxygenase 2 Inhibitors; Drug Interactions; Female; Humans; Male; Middle Aged; Osteoarthritis; Pyrroles; Renal Insufficiency; Sulfides | 2019 |
15 other study(ies) available for pyrroles and Kidney Failure
| Article | Year |
|---|---|
Response by Pei et al. to letters regarding article, "Pharmacokinetic study of imrecoxib in patients with renal insufficiency".
Topics: Humans; Pyrroles; Renal Insufficiency; Sulfides | 2020 |
Pronounced influence of presystemic metabolism on the metabolic disposition of imrecoxib in renally impaired patients.
Topics: Humans; Pyrroles; Renal Insufficiency; Sulfides | 2020 |
The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.
Topics: Acetonitriles; Adult; Aged; Area Under Curve; Blood Proteins; Dialysis Solutions; Female; Humans; Janus Kinase 1; Kidney; Male; Middle Aged; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Renal Dialysis; Renal Elimination; Renal Insufficiency | 2020 |
Dose investigation of imrecoxib in patients with renal insufficiency based on modelling and simulation.
Topics: Cyclooxygenase 2 Inhibitors; Humans; Pyrroles; Renal Insufficiency; Sulfides | 2020 |
HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Dyslipidemias; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Immunosuppressive Agents; Incidence; Indoles; Kidney Transplantation; Male; Middle Aged; Pyrroles; Renal Insufficiency | 2014 |
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Registries; Renal Insufficiency; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2014 |
Risks associated with sunitinib use and monitoring to improve patient outcomes.
Topics: Antineoplastic Agents; Female; Humans; Indoles; Male; Proteinuria; Pyrroles; Renal Insufficiency; Sunitinib | 2014 |
Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Proteinuria; Pyrroles; Renal Insufficiency; Republic of Korea; Retrospective Studies; Risk Factors; Sunitinib; Treatment Outcome | 2014 |
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2014 |
Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sunitinib | 2015 |
Pharmacokinetics of sunitinib in hemodialysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Humans; Indoles; Kidney Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Pyrroles; Renal Dialysis; Renal Insufficiency; Sunitinib; Young Adult | 2009 |
Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Renal Insufficiency; Sorafenib; Sunitinib | 2010 |
Atorvastatin and the dyslipidemia of early renal failure.
Topics: Adolescent; Adult; Aged; Atorvastatin; Body Mass Index; Cholesterol, LDL; Combined Modality Therapy; Creatinine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Linear Models; Male; Middle Aged; Pyrroles; Renal Insufficiency; Risk Factors; Treatment Outcome | 2003 |
Fatal hepatorenal failure and thrombocytopenia with SU5416, a vascular endothelial growth factor Flk-1 receptor inhibitor, in AIDS-Kaposi's sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Angiogenesis Inhibitors; Fatal Outcome; Humans; Indoles; Liver Failure; Male; Middle Aged; Pyrroles; Renal Insufficiency; Sarcoma, Kaposi; Skin Neoplasms | 2007 |
Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Renal Insufficiency | 1997 |